[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA822327B - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
ZA822327B
ZA822327B ZA822327A ZA822327A ZA822327B ZA 822327 B ZA822327 B ZA 822327B ZA 822327 A ZA822327 A ZA 822327A ZA 822327 A ZA822327 A ZA 822327A ZA 822327 B ZA822327 B ZA 822327B
Authority
ZA
South Africa
Prior art keywords
active compound
pharmaceutical composition
calcium
antagonistic
sustaining dose
Prior art date
Application number
ZA822327A
Inventor
Heinz Einig
Volker Buehler
Winfried Koch
Joachim Arthur Schwarz
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6129505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA822327(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA822327B publication Critical patent/ZA822327B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

1. A pharmaceutical composition which contains a calcium-antagonistic active compound, with or without additional active compounds, is intended for oral administration to produce a sustained action for continuous therapy and contains only the sustaining dose of active compound, bound to pharmaceutical auxiliaries, wherein the calcium-antagonistic active compound is Gallopamil or Verapamil and wherein, at the sustaining dose, the ratio of the constituents with rapid release of active compound to those with sustained release of active compound is from 1 : 0.6 to 1 : 6.
ZA822327A 1981-04-07 1982-04-05 Pharmaceutical composition ZA822327B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813113901 DE3113901A1 (en) 1981-04-07 1981-04-07 ACTIVE SUBSTANCE PREPARATION FOR ORAL APPLICATION

Publications (1)

Publication Number Publication Date
ZA822327B true ZA822327B (en) 1983-03-30

Family

ID=6129505

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA822327A ZA822327B (en) 1981-04-07 1982-04-05 Pharmaceutical composition

Country Status (17)

Country Link
EP (1) EP0063266B1 (en)
JP (1) JPS57175113A (en)
AT (1) ATE14076T1 (en)
AU (1) AU555093B2 (en)
CA (1) CA1184497A (en)
DE (2) DE3113901A1 (en)
DK (1) DK157482A (en)
ES (1) ES511208A0 (en)
FI (1) FI821253L (en)
GR (1) GR74770B (en)
HU (1) HU186855B (en)
IE (1) IE52985B1 (en)
IL (1) IL65328A (en)
NO (1) NO157204C (en)
NZ (1) NZ200244A (en)
PT (1) PT74705B (en)
ZA (1) ZA822327B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
LU86077A1 (en) * 1985-09-18 1987-04-02 Pharlyse Sa NEW GALENIC FORMS OF VERAPAMIL, THEIR MANUFACTURE AND THE MEDICINAL PRODUCTS CONTAINING THESE NEW GALENIC FORMS
LU86099A1 (en) * 1985-09-30 1987-04-02 Pharlyse EXTENDED RELEASE GALENIC FORMS OF VERAPAMIL, THEIR MANUFACTURE AND THE MEDICINAL PRODUCTS CONTAINING THEM
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
US4981871A (en) * 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
DE3809764A1 (en) * 1988-03-23 1989-10-05 Knoll Ag MIXTURE OF ALGINATES AND POLYACRYLATES AND THEIR USE
US5230901A (en) * 1988-03-23 1993-07-27 Knoll Ag Sustained release tablet of a mixture of alginates and polyacrylates
WO1990000391A1 (en) * 1988-07-13 1990-01-25 Knoll Aktiengesellschaft Depot-form of an alginate-based drug
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
DE3932378A1 (en) * 1989-09-28 1991-04-11 Knoll Ag SOLID MEDICAL FORM WITH A HIGH VERAPAMIL CONTENT
IT1264696B1 (en) * 1993-07-09 1996-10-04 Applied Pharma Res PHARMACEUTICAL FORMS INTENDED FOR ORAL ADMINISTRATION ABLE TO RELEASE ACTIVE SUBSTANCES AT A CONTROLLED AND DIFFERENTIATED SPEED
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154810B (en) * 1961-04-01 1963-09-26 Knoll Ag Process for the preparation of basic substituted phenylacetonitriles
DE1467781A1 (en) * 1963-07-15 1968-12-05 Boehringer Sohn Ingelheim Process for the production of coated tablets with extended release of active ingredients

Also Published As

Publication number Publication date
DE3113901A1 (en) 1982-10-28
NO821084L (en) 1982-10-08
AU8238482A (en) 1982-10-14
ES8307496A1 (en) 1983-08-16
EP0063266A2 (en) 1982-10-27
ES511208A0 (en) 1983-08-16
IE52985B1 (en) 1988-04-27
NO157204B (en) 1987-11-02
IL65328A0 (en) 1982-05-31
CA1184497A (en) 1985-03-26
NO157204C (en) 1988-02-10
PT74705B (en) 1983-11-14
ATE14076T1 (en) 1985-07-15
JPS57175113A (en) 1982-10-28
GR74770B (en) 1984-07-12
HU186855B (en) 1985-10-28
IE820812L (en) 1982-10-07
FI821253L (en) 1982-10-08
NZ200244A (en) 1984-08-24
PT74705A (en) 1982-05-01
EP0063266B1 (en) 1985-07-03
EP0063266A3 (en) 1983-05-04
AU555093B2 (en) 1986-09-11
DK157482A (en) 1982-10-08
DE3264519D1 (en) 1985-08-08
IL65328A (en) 1985-06-30
FI821253A0 (en) 1982-04-07

Similar Documents

Publication Publication Date Title
GR74770B (en)
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
ATE194987T1 (en) SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
DE60022895D1 (en) PDGF-RECEPTOR-KINASE-INHIBITABLE COMPOUNDS, THE PREPARATION, CLEANING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
ATE38991T1 (en) 2-POSITION-SUBSTITUTED 1,3PROPYLEDENDEPHOSPHONATE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch
DK0629400T3 (en) Idebenone-containing preparations for the treatment of Alzheimer's disease
DE3474774D1 (en) Therapeutic compositions for oral use containing stable s-adenosy1-l-methionine salts
KR890004705A (en) Antiviral agents
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
IE821258L (en) Anti-herpes medicaments
GB2162748B (en) Medicinal composition for the treatment or prevention of acne by oral administration
ATE18203T1 (en) (-)-15-DEOXYSPERGUALIN, ITS MANUFACTURE AND MEDICATIONS CONTAINING THIS ACTIVE SUBSTANCE.
HUT70033A (en) Process for producing synergetic pharmaceutical composition containing calcium channel blocking agent and calcium compound or vitamin d
ATE85218T1 (en) ORAL PHARMACEUTICAL FORM FOR THE TREATMENT OF HYPERTENSION WITH DILTIAZEM HYDROCHLORIDE ONCE DAILY.
IL87867A (en) Preparation of pharmaceutical compositions containing a 2,6-diamino-3-phenyl-azo-pyridine derivative
KR890007737A (en) Anti-caking agents
FR2567755B1 (en) NEW ANTI-TUMOR DRUG CONTAINING TRIACETOXY-1,8,9 ANTHRACENE AS ACTIVE INGREDIENT
KR890002058A (en) 2,4,6-tris-3-tert-butylamino-1, -3, -5-triazine for the prevention and treatment of epilepsy and anxiety